News
SUPN
35.21
+1.06%
0.37
Insider Sell: Supernus Pharmaceuticals
Insider Sell: Supernus Pharmaceuticals
MT Newswires · 11/15 17:09
Supernus Pharmaceuticals Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
Supernus Pharmaceuticals ( NASDAQ:SUPN ) Third Quarter 2022 Results Key Financial Results Revenue: US$177.4m (up 20...
Simply Wall St. · 11/11 10:52
Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09 00:25
BRIEF-Supernus Announces Third Quarter 2022 Financial Results
Reuters · 11/08 23:21
Supernus to Present at Two November Healthcare Conferences
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that...
GlobeNewswire · 11/08 22:30
Supernus Pharmaceuticals Q3 GAAP EPS $0.03, Sales $177.40M Beat $172.48M Estimate
Benzinga · 11/08 21:52
Supernus Pharmaceuticals GAAP EPS of $0.03 misses by $0.33, revenue of $177.35M beats by $4.87M
Seekingalpha · 11/08 21:20
-- Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q3 Revenue $177.4M, vs. Street Est of $172.5M
-- Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q3 Revenue $177.4M, vs. Street Est of $172.5M
MT Newswires · 11/08 16:40
-- GUIDANCE: (SUPN) SUPERNUS PHARMACEUTICALS Expects Fiscal Year 2022 Revenue Range $650M - $680M
-- GUIDANCE: (SUPN) SUPERNUS PHARMACEUTICALS Expects Fiscal Year 2022 Revenue Range $650M - $680M
MT Newswires · 11/08 16:33
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that...
GlobeNewswire · 10/25 20:30
FDA Rejects Supernus Pharma's Minimally Invasive Parkinson's Therapy
Benzinga · 10/10 13:27
Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Supernus Pharmaceuticals (NASDAQ:SUPN) is trading ...
Seekingalpha · 10/10 13:06
BRIEF-Supernus Pharmaceuticals Provides Regulatory Update On Spn-830
BRIEF-Supernus Pharmaceuticals Provides Regulatory Update On Spn-830
Reuters · 10/10 12:37
Supernus Provides Regulatory Update On SPN-830; Announced FDA Issued Complete Response Letter For SPN-830 New Drug Application
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
Benzinga · 10/10 12:32
Supernus Provides Regulatory Update on SPN-830
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that th...
GlobeNewswire · 10/10 12:30
Supernus Pharmaceuticals Says FDA Seeking More Info on Investigational Parkinson's Disease Device
Supernus Pharmaceuticals Says FDA Seeking More Info on Investigational Parkinson's Disease Device
MT Newswires · 10/10 10:37
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
Benzinga · 10/02 13:49
Supernus Pharmaceuticals On Sept. 9 Was Awarded $132M Department Of Veterans Affairs Contract
https://sam.gov/opp/763949eb6dcd4345a15a5d5d16c0ad23/view
Benzinga · 09/12 18:11
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Supernus Pharmaceuticals (NASDAQ:SUPN) has had a great run on the share market with its stock up by a significant 21...
Simply Wall St. · 09/07 13:03
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that...
GlobeNewswire · 08/31 20:00
More
Webull provides a variety of real-time SUPN stock news. You can receive the latest news about Supernus Pharma through multiple platforms. This information may help you make smarter investment decisions.
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. It is also developing a range of CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced Parkinson's disease (PD).